RIO DE JANEIRO, BRAZIL - The marketing authorization and the use of the medicine in Brazil is foreseen in a resolution by the Brazilian Health Regulatory Agency (ANVISA) published on Friday (29) in the Federal Gazette.
An oral solution based on cannabidiol (CBD), the medicine is the fourth with this active ingredient to be authorized for use in Brazil.
The authorized product has a concentration of 50 milligrams per milliliter with up to 0.2% of tetrahydrocannabidiol (THC) and must be imported pre-packaged and ready for exclusive distribution in pharmacies and drugstores, according to the resolution.
Interested parties will only . . .